All In Biotech

Drug Trial Radar · NCT04924608

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

A Phase III, Multicentre, International Study With a Parallel, Randomised, Double-blind, Placebo-controlled, 2 Arm Design to Assess the Efficacy and Safety of Selumetinib in Adult Participants With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas (KOMET)

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

145

Actual

Start

Nov 19, 2021

Primary completion

Aug 5, 2024

Study completion Feb 15, 2029

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Jun 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A global study to demonstrate the effectiveness of selumetinib in participants with NF1 who have symptomatic, inoperable plexiform neurofibromas.

Conditions

  • Neurofibromatosis 1
  • Plexiform Neurofibroma (PN)

Interventions

  • SelumetinibDrug

    Selumetinib oral capsules (10 mg and 25 mg)

  • PlaceboOther

    Placebo oral capsules for Selumetinib masking (10 mg and 25 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Confirmed Partial and Complete Response Rate (ORR) by End of Cycle 16 Using Volumetric MRI Analysis as Determined by ICR (Per REiNS Criteria) in Participants With NF1 Who Have Symptomatic, Inoperable PN.Time frame: From first dose up until progression (if it occurs prior to the end of Cycle 16), or the last evaluable assessment up to and including the end of Cycle 16, excluding MRI during prolonged study intervention interruption (defined as interruption >= 28 days)

Locations

34 sites in 13 countries. Site status is shown where the registry gives one.

  • Research Site

    Gainesville, Florida

  • Research Site

    Rockville, Maryland

  • Research Site

    St Louis, Missouri

  • Research Site

    Commack, New York

  • Research Site

    Melbourne, Australia

  • Research Site

    St Leonards, Australia

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Guangzhou, China

  • Research Site

    Shenyang, China

  • Research Site

    Créteil, France

  • Research Site

    Lyon, France

  • Research Site

    Toulouse, France

  • Research Site

    Hamburg, Germany

  • Research Site

    Tübingen, Germany

  • Research Site

    Würzburg, Germany

  • Research Site

    Milan, Italy

  • Research Site

    Naples, Italy

  • Research Site

    Roma, Italy

  • Research Site

    Minatoku, Japan

  • Research Site

    Nagoya, Japan

  • Research Site

    Shinjuku-ku, Japan

  • Research Site

    Bydgoszcz, Poland

  • Research Site

    Moscow, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Badalona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    London, United Kingdom

  • Research Site

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.